Medicine and Dentistry
Breast Cancer
100%
Biological Marker
61%
Neoplasm
46%
Breast Carcinoma
41%
Intraductal Carcinoma
40%
Tumor Infiltrating Lymphocyte
33%
Triple Negative Breast Cancer
30%
Malignant Neoplasm
28%
Oncology
26%
Immunoglobulin
25%
Clinical Trial
22%
Metastatic Carcinoma
21%
Immunohistochemistry
20%
Pathologist
19%
Breast Tumor
16%
Estrogen Receptor
16%
Gamma Urogastrone
16%
Diseases
16%
Biopsy Technique
14%
Recurrent Disease
13%
Programmed Death 1 Ligand 1
12%
Protein P53
12%
Targeted Therapy
12%
Stromal Tumor
12%
Programmed Cell Death
11%
Epidermal Growth Factor Receptor 2
11%
Epidermal Growth Factor Receptor
10%
Metastatic Breast Cancer
10%
Notch
10%
Circulating Tumor DNA
10%
Fine-Needle Aspiration
10%
Prognostic Factor
10%
Diagnosis
10%
Radiation Therapy
9%
Progesterone Receptor
9%
Cancer
9%
Immunity
8%
Lymphocyte
8%
Axilla
8%
Trastuzumab
7%
Tumor Microenvironment
7%
Lumpectomy
7%
Immunocompetent Cell
7%
Fluorescence in Situ Hybridization
7%
Lung Cancer
6%
Sentinel Lymph Node Biopsy
6%
Neoadjuvant Chemotherapy
6%
Mastectomy
6%
Macrophage
6%
Histopathology
6%
Keyphrases
Breast Cancer
73%
Ductal Carcinoma in Situ
48%
Immuno-oncology
36%
Human Epidermal Growth Factor Receptor 2 (HER2)
35%
Breast Carcinoma
35%
Tumor-infiltrating Lymphocytes
34%
Ductal Breast Carcinoma
31%
Oncology Biomarkers
31%
Tumor
29%
Programmed Death-ligand 1 (PD-L1)
24%
Triple-negative Breast Cancer
21%
Tumoricidal Activity
20%
Metastatic Breast Cancer
17%
Alveolar Macrophages
17%
Apoptosis
15%
Immunohistochemistry
15%
Pathologist
13%
Invasive Breast Carcinoma
12%
In Cancer
12%
Breast Tumor
12%
Stromal Tumor-infiltrating Lymphocytes
12%
Excision
11%
Lumpectomy
11%
Her2neu
11%
Prognostic Factors
11%
Estrogen Receptor
10%
Breast Cancer Patients
10%
B-cell Lymphoma 2 (Bcl-2)
10%
Core Needle Biopsy
10%
Fine-needle Aspiration
10%
Circulating Tumor DNA (ctDNA)
10%
Lung Cancer Patients
10%
Lung Cancer
10%
Non-small Cell Lung Cancer (NSCLC)
10%
Neoadjuvant Trials
10%
Institutional Experience
10%
Cancer Patients
10%
Peripheral Blood Monocytes
10%
Triple Negative
10%
Malignancy
9%
Axilla
9%
Trastuzumab
9%
Macrophages
9%
Clinical Trials
9%
Metastatic Disease
8%
Pathological Complete Response
8%
Notch1
8%
Prognostic Biomarker
8%
Accelerated Partial Breast Irradiation
8%
Interferon-α (IFN-α)
8%